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Abbreviations 
PD: Parkinson’s disease 
LRRK2: Leucine-rich repeat kinase 2 gene 
LRRK2: Leucine-rich repeat kinase 2 protein, dardarin 
SNCA: synuclein alpha gene 
SNCA: alpha-synuclein protein 
TCEANC2: transcription elongation factor A N-Terminal and central domain containing 2 gene 
TCEANC2: transcription elongation factor A N-Terminal and central domain containing 2 
protein 
MAPT: microtubule associated protein tau gene 
MAPT: microtubule associated protein tau protein 
SNP: single nucleotide polymorphism 
GWA: genome wide association 
AD: Alzheimer’s disease 
PSP: progressive supranuclear palsy 
EOPD: early-onset Parkinson’s disease 
LOPD: late-onset Parkinson’s disease 
PCR: polymerase chain reaction 
RFPL: restriction fragment length polymorphism 
OR: odds ratio 
CI: confidence interval 
LD: linkage disequilibrium 
Cdk5: Cyclin-dependent kinase 5 
iPSC:  induced pluripotent stem cell 
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Abstract 
Introduction: Parkinson’s disease is the second most common neurodegenerative disease. 
Lifestyle, environmental effects and several genetic factors have been proposed to contribute to 
its development. Though the majority of PD cases do not have a family history of disease, genetic 
alterations are proposed to be present in 60 per cent of the more common sporadic cases.  
Objective: The aim of this study is to evaluate the frequency of PD related specific risk variants 
of LRRK2, MAPT, SNCA and PARK10 genes in the Hungarian population. Out of the ten 
investigated polymorphisms three are proposed to have protective effect and seven are putative 
risk factors. 
Methods: For genotyping, TaqMan allelic discrimination and restriction fragment length 
polymorphism method was used. LRRK2 mutations were investigated among 124 sporadic PD 
patients and 128 healthy controls. MAPT and SNCA variant frequencies were evaluated in a group 
of 123 patients and 122 controls, while PARK10 variant was studied in groups of 121 patients and 
113 controls.  
Results: No significant difference could be detected in the frequencies of the investigated MAPT 
and PARK10 variants between the studied Hungarian PD cases and controls. The minor allele of 
the risk factor S1647T LRRK2 variant was found to be more frequent among healthy male 
individuals compared to patients. In the frequency of one of the investigated SNCA variant a 
significant intergroup difference was detected. The minor allele (A) of rs356186 is proposed to be 
protective against developing the disease. In accord with data obtained in other populations, the 
AA genotype was significantly more frequent among Hungarian healthy controls compared to 
patients. Similarly, a significant difference in genotype distribution was also found in comparison 
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of patients with late onset disease to healthy controls, which was due to the higher frequency of 
AG genotype among patients. 
Conclusion:  The frequencies of different gene variants show great differences in populations. 
Assessment of the frequency of variants of PD related genes variants is important in order to 
uncover the pathomechanisms underlying the disease, and to identify potential therapeutic 
targets. This is the first comprehensive study focusing on these genetic variants in the Hungarian 
population. Our results extend the knowledge on the world wide occurrence of these 
polymorphisms by demonstrating the occurrence of specific alleles and absence of others in 
Hungarian PD patients. 
Keywords: Parkinson’s disease, genetic risk factors, LRRK2, MAPT, SNCA, PARK10 
Highlights  
 G2385R and R1628P LRRK2 variants are absent in the Hungarian population. 
 The minor allele of the risk factor S1647T LRRK2 variant is more frequent among 
healthy male individuals compared to patients. 
 The protective rs356186 SNCA variant is significantly more frequent in homozygous 
form among controls than in PD patients. 
 The rs356186 SNCA variant is significantly more frequent in heterozygous form 
among LOPD patients compared to controls. 
 No signifcant dirrefence was detected in the frequency of rs1491923, R1398H, 
N551K, rs2583988, 1052553 and rs10788972 variants. 
 
1. Introduction 
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Parkinson’s disease (PD) is the second most common neurodegenerative disease, affecting 
millions of people worldwide  [1]. It is a multifactorial disease: several environmental, lifestyle 
and genetic factors have been suspected to contribute to its development. 5-10 % of PD cases are 
familial of which 30 percent is monogenic [2]. Regarding sporadic PD, only 3-5 percent of the 
cases are caused by single gene mutations. However, growing body of evidence suggest the 
involvement of genetic factors in 60 % of the more common idiopathic PD cases as well [3]. 
So far over 40 human genomic loci have been proven or proposed to be related to PD [3]. Several 
of these are also referred as ‘PARK’ and a number reflecting the order of their discovery to 
indicate the association with the disease. In this study, we investigated the presence of ten 
variants of four PARK genes: Leucine-rich repeat kinase 2 (LRRK2; PARK8), synuclein alpha 
(SNCA; PARK1 and 4), transcription elongation factor A N-Terminal and central domain 
containing 2 (TCEANC2; PARK10) and microtubule associated protein tau (MAPT) in Hungarian 
PD patients.  
The involvement of LRRK2 in PD was first described in a large Japanese family in 2002 [4]. 
Since then, several LRRK2 mutations have been identified, and alterations of this gene have been 
shown to be among the major causes of both familial and sporadic PD cases. Intensive research is 
ongoing to identify variants of the gene that act as risk factors in the disease. Two single 
nucleotide polymorphisms (SNPs) have been found to increase the risk of PD in Asian 
populations. One of them is a Gly to Arg substitution (G2385R), the other one an Arg to Pro 
change (R1628P). While both of these have been proven to be risk factors among Han Chinese, 
to date none of these variants has been found among Caucasians [5][6]. 
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In addition to G2385R and R1628P, a change of the 1647th amino acid Ser to Thr (S1647T) is 
also proposed to be a susceptibility factor for PD [7]. Its effect of increasing PD risk was reported 
in Asian populations [7], however, such association has not been found in the Caucasian 
populations investigated so far [8].  
Some of the LRRK2 polymorphisms on the other hand have been proposed to be protective 
against PD. Such variants are the Arg to His and Asn to Lys changes at the 1398th and 551th 
positions of the protein (R1398H and N551K). The occurrence of either of these in combination 
with the G2385R and R1628P allele is reported to diminish the otherwise elevated risk of the 
disease [7].  
Recently a Genome Wide Association (GWA) Study revealed that a common variability near the 
LRRK2 gene affects the risk of PD. The minor allele resulting from an A to G change (indicated 
in forward orientation, rs1491923) was found to be more common among both Caucasian and 
Asian PD patients then their healthy controls [9].  
 Similarly to LRRK2, several variants of the SNCA gene have been proposed to be risk-, or 
protective factors regarding PD. In fact, mutations of the SNCA gene were the first genetic 
variants identified as causes of autosomal dominantly inherited familial PD. Two intronic 
variants of the gene: rs2583988 and rs356186 are proposed risk-, and protective factors against 
PD, respectively. The role of these variants among sporadic PD patients of Caucasian origin is 
controversial. Association and also the lack of it between these variants and the disease have been 
reported in several studies involving Caucasian subjects [10][11][12][13][14]. 
The MAPT gene is located on the long arm of chromosome 17, at a site of an approximately 900 
kb common inversion [15] that results in two distinct haplotypes: the non-inverted H1 and the 
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inverted H2. The H1 haplotype has been associated with numerous diseases which are often 
referred as taupathies: Alzheimer’s disease (AD), sporadic fronto-temporal dementia, progressive 
supranuclear palsy (PSP) and PD.  A common pathological hallmark of these is the accumulation 
of MAPT neurofibrillary tangles in nerve cells [15]. The association of H1 with PD is, however, 
still an intriguing question. Several studies involving subjects of different nationalities reported 
no, or marginal association between the occurrence of the H1 haplotype and PD (reviewed in 
[16]).  SNPs suitable of marking the inversion have been identified: a G to A change (rs1052553) 
is an indicator of the H1 haplotype [15].  
The long arm of chromosome 1 containing the PARK10 region with the locus of TCEANC2 gene 
has also gathered interest concerning its role in PD. The link between PD and this region was 
identified first approximately 15 years ago [17], and since then, a linkage disequilibrium (LD) for 
a block of 100 kb was identified in the region [18]. The SNP rs10789972, located in the 
TCEANC2 gene, was found to show association with sporadic PD in American population [18] 
but there was no association detected among subjects of Han Chinese origin [19][20]. 
Allelic variants of PD-related genes are found in widely different frequencies among different 
populations, making it difficult to clarify the genuine effect of specific variants on the 
development of PD in distinct populations. It is important therefore to evaluate the occurrence of 
specific genetic alterations in homogenous study groups of different nationalities. Information on 
the occurring mutations in a population can be beneficial for understanding more of the 
pathological mechanisms underlying the disease. Moreover, the identification of gene variants 
characteristic for a population might be useful also in applying the most fitting therapeutic 
methods and developing new therapeutic approaches. 
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The aim of our study was to assess the frequency of LRRK2, SNCA, MAPT and TCEANC2 
mutations in sporadic PD patients in Hungary. All combined, we assessed the occurrence of ten 
mutations which vary in their effects as some are risk factors and others protective. We selected 
SNPs that are either the most intensively studied (as they have been proven to play a role in the 
disease in certain populations) or have been recently identified as potential risk factors. To our 
knowledge, this is the first throughout study focusing on the prevalence of these PARK gene 
variants in Hungary.  
 
2. Material and methods 
2.1. Subjects 
2.1.1. LRRK2 variants 
124 sporadic PD patients were involved in the study (mean age: 66.5 ± 9.5 years, male-female 
ratio 61:63) (Table 1). Depending on the first appearance of symptoms, two groups were formed: 
early-onset (EOPD; disease onset ≤ 60 years) and late-onset (LOPD; disease onset > 60 years) 
PD patients. The EOPD group comprised 68, the LOPD 56 individuals. The age at disease onset 
was 51.1 ± 7.4 and 68.7 ± 5 years, respectively. The control group consisted of 128 healthy 
volunteers (mean age of 64.5 ± 9.6 years, male-female ratio 61:67). 
2.1.2. SNCA and MAPT variants 
The frequencies of the rs2583988 and rs356186 SNPs of SNCA and rs1052553 variant of MAPT 
were assessed in the groups of 123 sporadic PD patients (mean age: 66,5 ± 9,5 years, male-
female ratio 60:63) and 122 healthy controls (mean age: 64,3 ± 8,8 years, male-female ratio 
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56:66) (Table 1). Based on the appearance of the first symptoms, the patient’s group was divided 
into two subgroups. The EOPD (disease onset ≤ 60 years) group comprised 67, the LOPD 
(disease onset > 60 years) group 56 patients. The age at disease onset was 51,1 ± 7,5 and 68,7 ± 5 
years, respectively 
2.1.3. TCEANC2 polymorphism 
The frequency of the rs10789972 SNP of the TCEANC2 gene in the PARK10 locus was 
evaluated among 121 sporadic PD patients (mean age: 66,5 ± 9,6 years, male-female ratio 59:62) 
and 113 healthy controls (mean age: 64,9 ± 8,1 years, male-female ratio 50:60) (Table 1). Among 
PD patients, 66 individuals reported the first disease symptoms at or under the age of 60 years 
(EOPD, disease onset 51 ± 7,5 years). In the case if the other 55 patients the first symptoms 
appeared after the age of 60 years (LOPD, disease onset 68,7 ± 5,1 years).  
In all study groups, the diagnosis of PD was set up based on medical history and physical 
examination by movement disorder specialists. All control individuals lacked history of 
neurological and psychiatric disorders. 
Informed consent was obtained from all study participants. The study is in full accordance with 
the Helsinki Declaration and was approved by the Medical Research Council Scientific and 
Research Ethics Committee.  
2.2. DNA isolation 
The standard desalting method [21] was used for genomic DNA isolation from peripheral blood. 
The extracted DNA was stored at -20 oC. 
2.3. Restriction fragment length polymorphism  
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For the genotyping of R1628P and G2385R variants polymerase chain reaction (PCR) followed 
by restriction fragment length polymorphism (RFLP) analysis was implemented. The sequences 
of the primers used for generating PCR products and annealing temperatures can be provided on 
request (please contact the Corresponding Author). For the investigation of G2385R and R1628P 
SNPs 170 bp and 419 bp PCR products were generated, respectively. After amplification, the 
PCR products were digested with restriction enzymes at 37 ◦C overnight. AccI restriction enzyme 
was used for the detection of G2385R, and BstUI for R1628P. DNA fragments were then 
detected on 2% agarose gel electrophoresis, visualizing the bands with ECO Safe alternative gel 
stain. Wild-type G2385R samples remained undigested, resulting in one, 170 bp DNA fragment. 
In the case of heterozygous samples three fragments (170,123 and 47 bp), while in the case of 
homozygous mutants, two (123 and 47 bp) fragments could be detected. Opposite to this, in the 
case of the R1628P SNP digestion of homozygous wild-type samples resulted in the generation 
of two (263 and 156 bp) DNA fragments. The partial digestion of heterozygous samples yielded 
three bands (419, 263 and 156 bp), while PCR products of homozygous mutant samples remained 
undigested resulting in one detectable band (419 bp).  
2.4. TaqMan allelic discrimination method  
The analysis of R1398H, N551K, S1647 and rs1491923 LRRK2 variants and all the investigated 
MAPT, SNCA and TCEANC2 variants was performed with the use of TaqMan allelic 
discrimination assays obtained from Thermo Fisher Scientific. PCR reactions were run on Bio-
Rad real-time thermal cycler CFX96. The reaction conditions can be obtained on request (please 
contact the Corresponding Author).  
2.5. Statistical analysis 
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For statistical analysis GraphPad Prism 6.01 statistics software was used. For the analysis of 
genotype and allele frequencies Chi-square (χ2) test or Fisher’s test was used. Odds ratio (OR) 
with a 95% confidence interval (95% CI) was implemented for the analysis of the association 
between PD and genotype frequencies. P less than 0,05 was considered statistically significant.  
 
3. Results 
3.1. Putative risk factor LRRK2 mutations (G2385R, R1628P, S1647T and rs1491923) 
The G2385R and R1628P variants were found to increase the risk of developing in PD, however, 
seem to be absent or extremely rare in Caucasian populations. In accord with this, we did not 
found any of these SNPs to be present in either of our study groups (Suppl. Table 2.). 
The S1647T substitution results from a T to A change in exon 34. The minor allele (A) of the 
variant was found to be a risk factor of PD in several Asian populations. However, such relation 
has not been identified in Caucasian populations. The genotype and allele distribution of this 
variant was similar in both study groups (Suppl. Table 3.). The difference was not significant 
when comparing EOPD and LOPD patient subgroups to controls. When analyzing the genders 
separately, the comparison of female patients to healthy controls showed no significant difference 
regarding both genotype and allele frequencies. However, when analyzing the genotype 
distribution of male patients in comparison with the corresponding control group, a trend towards 
higher AA frequency could be observed in healthy controls. Comparing allele frequencies of the 
same groups revealed the minor (A) allele to be significantly more frequent among healthy male 
individuals (χ2=6,06; p=0,014) (Suppl. Table 3.). 
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The SNP rs1491923 is an A to G change (indicated in reverse orientation), affecting a site 
0.17Mb upstream of LRRK2 gene [9]. Its role as a predisposing factor PD was proposed recently 
based on the results of a GWAS study [9]. We found both genotype and allelic distribution of this 
variant to be similar in our patient and control group (Suppl. Table 4.). Comparison of subgroups 
generated by separating our two main study groups (PD and control) either by gender or by the 
age of disease onset did not reveal significant difference either in genotype or in allele 
frequencies (Suppl. Table 4.). 
3.2. Protective LRRK2 variants (R1398H and N551K) 
The R1398H and N551K LRRK2 variants were found to diminish the increased risk of the disease 
in G2385R and R1628P carriers [7]. We did not find any significant difference between either the 
genotype or allele frequencies of the R1398H or N551K variants between the control and PD 
group (Suppl. Table 5.). Allele and genotype frequencies were also similar after stratification by 
gender or by age at disease onset. We found these variants to be in LD, as except for one case in 
our group of healthy controls, the R1398H and N551K substitution always occurred 
simultaneously (Suppl. Table 5.).  
3.3. SNCA and MAPT gene variants 
The rs356186 SNP is an intronic G to A change in the SNCA gene, of which the minor A allele is 
proposed to be protective in PD. Comparing the genotype distribution of our control and patients’ 
group there was a significant difference (χ2 =7,65; p=0,022) (Suppl. Table 6.). This intergroup 
difference was due to the higher relative frequency of the AA genotype among healthy 
participants in comparison to patients (AA vs. GG+AG, Fisher’s test: p=0,019, OR: 0,12, CI 
(95%): 0,014-0,95). A significant difference in genotype distribution was also found when 
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comparing the LOPD group to healthy controls (χ2 =6,14; p=0,046) (Suppl. Table 6.). This 
difference is a consequence of higher frequency of AG genotype among LOPD patients (AG vs. 
GG+AA; χ2 =5,07; p=0,024). No significant difference in genotype or allele distribution could be 
detected in other study setups. 
No significant difference was found in genotype or allele frequency of rs2583988 SNP of SNCA 
and the studied MAPT variant (rs1052553) in either comparison (Suppl. Table 7. and 8.).  
3.4. TCEANC2 gene variant 
Both allele and genotype distribution of the rs10789972 SNP was similar in the PD and control 
group, revealing no significant difference (Supp. Table 9.). Similarly, no significant difference 
was found when comparing the EOPD, LOPD, male or female patients to the corresponding 
control groups. 
4. Discussion 
The aim of our study was to assess the frequency of six LRRK2, two SNCA, a haplotype marking 
MAPT and PARK10 variants in Hungarian sporadic PD patients. To our knowledge this is the 
first comprehensive study focusing on these gene variants in Hungary.  
The LRRK2 gene is localized on the long arm of chromosome 12. LRRK2 – also known as 
dardarin – is a large protein, built up of more, than 2500 amino acids. It is a representative of the 
ROCO superfamily and consists several domains, of which two (a kinase and GTPase) are 
enzymatic. Though the exact physiological function of the protein needs further elucidation, 
LRRK2 is suggested to serve as a scaffolding protein, to be involved in the process of neurite 
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outgrowth, maintenance of the cytoskeleton, vesicle transport and degradation of autophagic 
protein (reviewed in [22]).  
Among the investigated LRRK2 variants four are putatively, or among some populations proven 
risk factor variants, and two SNPs have been found to have protective effects among certain 
circumstances. 
Even today, data regarding the LRRK2 mutations that might act as risk factors in PD is 
inconclusive. Out of the more, than 100 SNPs in LRRK2 gene G2385R and R1628P are the only 
validated coding susceptibility alleles for PD [23]. The Gly to Arg substitution at the 2385th 
amino acid position (G2385R) causes a two-fold increase in PD risk, while the Arg to Pro amino 
acid change at position 1628 (R1628P) causes an even bigger increase in the possibility of 
developing the disease [24]. Our results showing that both of these variants are absent in our 
study groups are in accord with literature data. The R1628P and G2385R substitutions have been 
found only in the Asian, but not in Caucasian populations [25][23][26]. 
The G3285R substitution is located towards the C terminus of the protein in the WD40 domain. 
As this domain takes part in protein-protein interactions, one might suppose that the amino acid 
change leads to alterations in the interactions with substrates and other regulatory proteins [5]. 
Functional studies revealed that under oxidative stress cells with the G2385R substitution showed 
a higher rate of apoptosis compared to the wild type [27]. The mutation might also increase the 
kinase activity of the protein, however, the data regarding this issue are inconclusive [7][28]. The 
R1628P mutation affects the COR domain of the protein and there is data suggesting it to cause a 
diminishment in GTPase activity [28]. Besides changes in the GTPase, the R1628P substitution 
was also found to increase the kinase activity of dardarin [7]. This is probably because of the 
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increased binding affinity of LRRK2 with Cyclin-dependent kinase 5 (Cdk5) due to the amino 
acid substitution, which leads to the phosphorylation of LRRK2 at the S1627 site, resulting in 
increased kinase activity of the protein [29]. Similarly, to G2385R, R1628P mutant cells were 
found to be more prone to apoptosis under oxidative stress when compared to wild type [30].  
S1647T is another variant, which the effect of increasing the risk towards PD was first spotted in 
a Han Chinese population [7]. This Ser to Thr substitution is located in the COR protein domain, 
which together with the adjacent Roc domain forms the tandem Roc-COR domain, accounting 
for the GTPase function of LRRK2. Existing data suggest that GTP binding is essential for the 
activation of kinase function of this protein, therefore mutations affecting the GTPase domain 
might have effects on kinase function as well [28]. Other reports indicate that the dimeric form is 
essential for kinase activity [28]. Considering that the COR domain is a core element in protein 
dimerization [31], mutations affecting this domain could have effects on kinase activity either by 
changes in autophosphorylation or protein conformation. However, further studies are necessary 
for the elucidation of the effects of the S1647T mutation, as so far no changes have been found in 
kinase activity in relation with this variant [7].  
Our findings, that there is no significant association between the ST1647T LRRK2 variant and PD 
in our cohort, is in accord with literature data available regarding Caucasian populations, as no 
significant association was found in Finnish and Greek study groups either [8]. Our result of 
higher frequency of the minor allele among male controls compared patients is in contrast with 
literature data. However, this conflicting result might be due to the relatively small sample size.    
Rs1491923 is an A to G (forward orientation) change 0.17 Mb upstream the gene. The possible 
significance on developing PD of this common intronic variant was proposed by a GWA study. It 
16 
 
was found that the minor allele of this SNP was more common among American, German and 
British PD patients [9]. Findings obtained by the use of an induced pluripotent stem cell (iPSC) 
model of idiopathic PD suggest that this variant might have detrimental effect on mitochondrial 
protein clearance and autophagy [32]. Though our results do not add to these findings, the 
possible risk effect of this variant on the disease cannot be excluded. In order to clarify such 
associations further genotype analysis of independent sample groups of different populations is 
clearly warranted.  
Besides risk factor mutations there are variants of the LRRK2 gene which seem to have a 
protective effect against the development of PD. Such variants are the R1398H and N551K 
substitutions, located in the ROC domain and armadillo repeat region of the protein, respectively. 
A study involving Asian patients and controls found these variants to be in LD and were 
significantly more frequent among PD patients [7]. The same study revealed a prominent 
reduction in the otherwise increased disease risk due to the presence G2385R and R1628P 
polymorphisms in individuals who simultaneously were carriers of either the R1398H or N551K 
SNPs [7]. Moreover, appearance of either of the protective variants could largely negate the risk 
of a R1628P carrier, resulting in an OR 1.5-1.6 instead of 1.9 [7]. This could partly be explained 
by the diminished kinase activity of R1398H mutant dardarin, which might be able to compensate 
the elevated enzyme function, a result of R1628P and/or G2385R substitutions [7]. In Caucasian 
population no significant difference was found in the frequencies of these variants between PD 
patients and healthy individuals [8]. Our observations corroborate with data published on Greek 
and Finnish populations [8] in finding no significant difference among PD patients and controls. 
Our data are also consistent with the findings of others in regard the LD these gene variants show 
[7].  
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The SNCA gene is located on the long arm of chromosome 4 and consisting of 10 exons it spans 
over 114 kb. The product of the gene is the 140 amino acid alpha-synuclein (SNCA), a major 
component of the PD-related Lewy bodies. Accumulation of the protein is proposed to contribute 
to the selective loss of dopaminerg neurons seen in PD due to the increased sensitivity of the cells 
to dopamine toxicity [33]. Mutations of the SNCA gene were the first genetic alterations 
identified to cause autosomal dominant PD. Since then several SNPs within the gene have been 
proposed to contribute to, or, in some cases, decrease the risk of developing the disease. The SNP 
rs2583988 is an intronic C/T base change. The minor allele of the variant was found to occur at a 
significantly higher frequency among PD patients compared to controls in studies involving 
individulals of Caucasian origin [10][11][12]. However, there are also data representing for the 
lack of such association between PD and the polymorphism [13]. In accord with our findings, 
association between the minor allele frequency of rs2583988 and PD was not found among 
German [13] or Irish [14] patients. 
Rs356186 is an A/G change (indicated in forward orientation) which is also located in the 
intronic region of the SNCA gene. The presence of the minor allele is proposed to be a protective 
factor against developing PD. This assumption is based on the detection of the minor allele 
significantly more frequent among healthy controls compared to PD patients in Irish [14], Italian 
[10] and populations of Northern Central and Southeastern European origin [11]. However, no 
significant difference was detected between controls and patients in a study involving German 
participants (except when comparing the frequency between female PD patients and the 
corresponding control individuals) [13]. Recently a meta-analysis was conducted with the aim to 
find the most relevant SNCA SNPs in PD [34]. Zang et al. analysed the significance level of the 
different variants from various studies, and based on that, defined the polymorphisms rs2583988 
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and rs356186 as recommended and most recommended SNCA SNPs, respectively [34]. The same 
study also concluded that heterozygotes of the protective SNCA variant (rs356186) greatly 
contribute to the effect of this SNP since in the overall analyzed populations the dominant model 
of the variants showed significant difference [34]. These findings are in accord with our data, as 
we found that the significant difference in genotype distribution between LOPD group and 
healthy controls was a consequence of higher frequency of AG genotype among LOPD patients. 
We also detected a significantly higher relative frequency of the AA genotype among healthy 
participants in comparison to patients. 
MAPT gene on the long arm of chromosome 17 is located at a site of a common inversion that 
results in two haplotypes. The more common haplotype referred as H1, the rarer as H2 [35]. 
Several genes are localized in the approximately 900 kb affected region of chromosome that 
results in H1 and H2 haplotype formation [36]. One of the most studied one of these genes is 
MAPT due to its linkage with several disorders including neurodegeneration [37]. The H1 
haplotype was found to show higher transcriptional activity being stronger at initiating 
transcription thus resulting in increased expression of the MAPT gene [38].  In accord with this, 
the H1 haplotype has been associated with neurological diseases such as sporadic frontotemporal 
dementia, PSP, AD and PD – which all share a pathological hallmarks of accumulated MAPT 
neurofibrillary tangles in neurons [39]. However, the role of H1 haplotype in PD risk is 
controversial. Several studies of various populations reported no, or only marginal significance of 
the variant in PD (reviewed in [37]). Our results are in accord with those which found no 
significant association between the H1 haplotype and PD involving British [40], Swedish [41] 
and Taiwanese [42] populations (reviewed: [16]). 
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The TCEANC2 is one of the genes located in the PARK10 region on chromosome 1. The gene 
spans approximately 58 kilobases and contains 6 exons. The exact function of TCEANC2 is still 
unknown. Data suggest its involvement in RNA processing [18]. The relationship of the PARK10 
locus and PD was first described in a large Icelandic family [17]. Since then, a LD block of 100 
kilobase in this region was found to be associated with the disease [18]. The SNP rs10789972, 
located in the TCEANC2 gene, was found to show the strongest association with sporadic PD in 
American population [18]. However, associaton between the variant and PD has not been found 
in Han-Chinese population [19][20]. Our findings do not indicate association of the variant and 
PD, however, further studies focusing on elucidating this question are strongly warranted. 
5. Conclusions 
A growing body of evidence suggests contribution of genetic factors in the development of PD. 
Besides the well established pathogenic mutations, several gene variants have been proposed to 
be risk factors, or, on the contrary, to play a protective role in the disease. Such assumptions are 
mainly based on genome wide association studies. The heterogeneity of the study groups 
included in these studies might cover frequency differences that might exist among different 
populations in respect of specific gene variants. Therefore it is important that findings of GWA 
studies are tested in specific populations. Our results are from the first comprehensive study 
focusing on the LRRK2, SNCA, MAPT and PARK10 risk and protective variants in the Hungarian 
population. We believe that these results represent a valuable contribution to the evaluation of the 
world wide significance of these genetic variants.  
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Table 1.  
Gene   
Total number of 
participiants 
Age (mean±SD; 
years) 
Male/female 
ratio 
Disease onset 
(EOPD/LOPD ratio) 
LRRK2 
PD 124 66,5 ± 9,5  61/63 68/56 
Control 128 64,5 ± 9,6  61/67   
SNCA and MAPT 
PD 123 66,5 ± 9,5  60/63 67/56 
Control 122 64,3 ± 8,8  56/66   
TCEANC2 
PD 121 66,5 ± 9,6 59/62 66/55 
Control 113 64,9 ± 8,1  50/60   
 
Demographic data of the study groups. Abbreviations: PD: Parkinson's Disease; EOPD: early-
onset Parkinson's Disease; LOPD: late-onset Parkinson's Disease; SD: standard deviation.
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